Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR046713)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (AI046712, AI044938)
Scleroderma Foundation (N/A)
Article History
Received: 7 April 2019
Accepted: 10 July 2019
First Online: 19 November 2019
Competing interests
: F.J.B. has been acting as a consultant for Astra Zeneca, Janssen and EMD Serono but has no other conflicts. M.K.C. has served as a consultant for Astra Zeneca, Bristol-Myers Squibb, Janssen, Lilly and Novartis. L.B.I. serves as a consultant for Lilly but does not accept any personal compensation.